mProX™ Human CD80 Stable Cell Line

Biosafety Level

Level 1

Activity

Yes

Quantity

10⁶ cells per vial

Applications

CD80 is a marker used to study the phenotypic characteristics and plasticity of alveolar macrophages in rats with metabolic syndrome. It has been found that metabolic syndrome decreases the number of alveolar macrophages with the M1 phenotype, but does not affect their phenotypic plasticity in culture. However, under the action of M2 reprogramming factors, these cells demonstrate a wide range of phenotypic plasticity by the CD80 marker. CD80 is also involved in the production of cathepsins B and S by macrophages and their polarizations. A rhenium(I)-diselenoether drug has been shown to decrease the expression of cathepsins B and S in M1 macrophages and increase the expression of M1 markers while decreasing the expression of M2 markers. In cystic vestibular schwannoma, CD80 expression in cyst fluid correlates with the expression of monocyte chemotactic protein-1 (MCP-1) in tumor tissue, suggesting a role in monocyte recruitment and macrophage polarization. Additionally, CD80 is used as a biomarker in the evaluation of the efficacy and safety of cosibelimab, an anti-PD-L1 antibody, in metastatic cutaneous squamous cell carcinoma. Cosibelimab demonstrated a clinically meaningful objective response rate and duration of response with a manageable safety profile. Finally, CD80 is involved in tumor-specific immunity for colon tumor treatment. Reactive oxygen species-sensitive biodegradable mesoporous silica nanoparticles loaded with a therapeutic vaccine (TheraVac) containing CD80 induce the maturation and activation of dendritic cells, leading to robust antitumor immune responses and complete cure of colon tumors in mice.